collection
https://read.qxmd.com/read/20864909/anemia-in-heart-failure-should-we-supplement-iron-in-patients-with-chronic-heart-failure
#21
REVIEW
Elisabet E Kaldara-Papatheodorou, John V Terrovitis, John N Nanas
Anemia has been identified as an independent prognostic factor of both morbidity and mortality for patients with congestive heart failure (CHF). The association between anemia and adverse outcomes has raised the hypothesis that anemia correction might lead to an improvement in the prognosis of patients with CHF. Nevertheless, data from large randomized trials about the effect of anemia correction on patient outcome are still lacking. Numerous clinical studies, randomized and nonrandomized, have evaluated the efficacy of erythropoietin or iron supplementation for treating anemia in patients with CHF, and their effect on patient symptoms and functional status...
September 2010: Polskie Archiwum Medycyny Wewnętrznej
https://read.qxmd.com/read/20630411/the-economic-burden-of-anemia-in-heart-failure
#22
REVIEW
Richard K Spence
Anemia is a complex issue in patients with heart failure (HF). In past years, clinicians accepted anemia as a given or an "accessory" diagnosis in HF patients. This attitude has changed since understanding of the causes and morbidity of anemia in HF has improved and with the introduction of targeted treatments. Increasing health care costs have stimulated vigorous debate about the cost-effectiveness of such treatments. It behooves clinicians to understand the effectiveness of specific treatments, risks and benefits, and costs...
July 2010: Heart Failure Clinics
https://read.qxmd.com/read/20630412/future-directions-in-management-of-anemia-in-heart-failure
#23
REVIEW
Anil K Agarwal, Stuart D Katz
Anemia in patients with heart failure (HF) may be caused by several factors, including hemodilution, iron or erythropoietin deficiency, and chronic kidney disease. Published pilot studies of erythropoiesis-stimulating agents (ESAs) and intravenous iron therapy in anemic heart failure patients demonstrate improvement in surrogate markers of functional capacity and quality of life, and reasonable safety profile during short-term use. However, the long-term safety of ESA in treatment of anemia in patients with HF remains a concern due to documented harmful side effects of ESA in anemic patients with advanced chronic kidney disease and cancer...
July 2010: Heart Failure Clinics
https://read.qxmd.com/read/20630402/pathophysiology-of-anemia-in-heart-failure
#24
REVIEW
Inder S Anand
Renal dysfunction and neurohormonal and proinflammatory cytokine activation appear to contribute to anemia of chronic disease in most patients, resulting in inappropriate erythropoietin production and defective iron utilization. Under normal conditions, reduced tissue oxygenation caused by chronic anemia results in non-hemodynamic and hemodynamic compensatory responses to enhance oxygen carrying capacity. Erythropoiesis is the predominant non-hemodynamic response to hypoxia, but because erythropoiesis is defective in heart failure, hemodynamic mechanisms may predominate in chronic severe anemia...
July 2010: Heart Failure Clinics
https://read.qxmd.com/read/21593950/-diagnosis-and-treatment-of-anemia-in-heart-failure-patients
#25
REVIEW
Giovanna Santilli, Luigi Tarantini, Pierangelo Baio, Michele Senni
Anemia is a common comorbidity in patients with acute and chronic heart failure (HF) with preserved and reduced systolic function. It is recognized as a new therapeutic goal in HF since the reduction in hemoglobin levels is considered a significant independent predictive factor of mortality and hospitalization. At present, it is difficult to determine the real magnitude of the problem in terms of actual incidence and prevalence as no consistent definition of anemia associated with HF does exist, and a variety of hemoglobin thresholds have been used in clinical trials and epidemiological studies...
May 2011: Giornale Italiano di Cardiologia
https://read.qxmd.com/read/17688854/-anemia-in-heart-failure-pathophysiology-pathogenesis-treatment-and-incognitae
#26
REVIEW
Carlos Caramelo, Soledad Justo, Paloma Gil
Although anemia now occupies an important place in our present understanding of the pathogenesis of heart failure, the condition is surrounded in mystery. Anemia is highly prevalent in patients with heart failure and is of great clinical significance. However, the treatment targets for anemia in patients with heart failure have still not been accurately defined. The present article reviews of the clinical and pathophysiological characteristics of anemia in this context. Particular emphasis has been placed on cellular and molecular regulatory mechanisms, and their implications for treatment...
August 2007: Revista Española de Cardiología
https://read.qxmd.com/read/20630401/epidemiology-of-anemia-in-heart-failure
#27
REVIEW
W H Wilson Tang, P S Daniel Yeo
Anemia is being increasingly recognized as an important comorbidity in patients with heart failure. Despite wide variations in defining anemia, approximately one-fifth to one-third of patients with heart failure may experience anemia at a given time. The prevalence may increase to more than half of patients in the setting of severe heart failure, and it may differ with different settings. Meanwhile, up to a fifth of patients may experience new-onset anemia, even though most cases may resolve over time. Different factors contribute to the development of anemia, including increasing age, renal insufficiency, hemodilution, chronic inflammation, and increasing heart failure disease severity...
July 2010: Heart Failure Clinics
https://read.qxmd.com/read/18691487/anemia-and-heart-failure-a-community-study
#28
JOURNAL ARTICLE
Shannon M Dunlay, Susan A Weston, Margaret M Redfield, Jill M Killian, Véronique L Roger
PURPOSE: Anemia is an important comorbidity in heart failure and has been associated with increased mortality. The goals of this study were to define the prevalence of anemia in a community population with heart failure, examine trends in prevalence over time, and evaluate the role of anemia in patients with heart failure with preserved and reduced ejection fraction. METHODS: Two cohorts of Olmsted County residents with heart failure were examined. The retrospective cohort included incident heart failure cases from 1979 to 2002 (n=1063)...
August 2008: American Journal of Medicine
https://read.qxmd.com/read/20973926/erythropoiesis-stimulating-agents-and-heart-failure
#29
REVIEW
Erik Lipšic, Peter van der Meer, Dirk J van Veldhuisen
Anemia is a common comorbidity in heart failure (HF) patients. Its occurrence and severity are associated with worse prognosis. Although the etiology of anemia is multifactorial, inappropriate erythropoietin (EPO) production and/or bone-marrow resistance to EPO appear crucial in majority of anemic HF patients. Consequently, treatment based on this pathophysiological background may prove to be most effective and beneficial. In a number of smaller clinical studies, administration of erythropoiesis-stimulating agents (ESAs) to anemic HF patients improved a number of surrogate endpoints, including left ventricular function, exercise capacity, renal function, and different quality of life parameters...
August 2011: Cardiovascular Therapeutics
https://read.qxmd.com/read/21977269/anemia-and-heart-failure-a-cause-of-progression-or-only-a-consequence
#30
JOURNAL ARTICLE
Marco Metra, Savina Nodari, Tania Bordonali, Silvia Bugatti, Benedetta Fontanella, Carlo Lombardi, Alberto Saporetti, Giulia Verzura, Rossella Danesi, Livio Dei Cas
Anemia is one of the most frequent co-morbidities in the patients with heart failure. Its prevalence increases from 4-7% in the subjects with asymptomatic left ventricular dysfunction to >30% in the patients with severe heart failure. Renal insufficiency, activation of inflammatory mediators, and treatment with renin-angiotensin antagonists seem to be its main determinants. The results of many studies agree in showing that anemia is a powerful independent determinant of survival in patients with heart failure...
2007: Heart International
https://read.qxmd.com/read/20557272/treating-anemia-in-heart-failure-patients-a-review-of-erythropoiesis-stimulating-agents
#31
REVIEW
Benjamin P Geisler
IMPORTANCE OF THE FIELD: Prevalence of chronic heart failure (CHF) is increasing, and despite improvements in the past decade the prognosis in terms of mortality and health-related quality of life remains poor. Anemia is often found concomitantly in CHF patients. AREAS COVERED IN THIS REVIEW: Erythropoiesis-stimulating agents (ESAs) are a new treatment option for these anemic CHF patients, promising to decrease mortality and hospitalizations, and increase health-related quality of life...
August 2010: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/20670844/correcting-anemia-in-heart-failure-the-efficacy-and-safety-of-erythropoiesis-stimulating-agents
#32
REVIEW
Patrick R Lawler, Kristian B Filion, Mark J Eisenberg
BACKGROUND: Randomized controlled trials (RCTs) evaluating the efficacy and safety of erythropoiesis-stimulating agents (ESAs), including erythropoietin and darbepoetin, among patients with chronic heart failure (CHF) and anemia have yielded heterogeneous results, and important safety questions remain unanswered. We therefore undertook a meta-analysis to examine the effects of ESAs in this population. METHODS AND RESULTS: We systematically searched EMBASE, Medline, the Cochrane Library, ClinicalTrials...
August 2010: Journal of Cardiac Failure
https://read.qxmd.com/read/21570510/erythropoietin-as-a-treatment-of-anemia-in-heart-failure-systematic-review-of-randomized-trials
#33
REVIEW
Dipak Kotecha, Katherine Ngo, Julia A E Walters, Luis Manzano, Alberto Palazzuoli, Marcus D Flather
BACKGROUND: Anemia in heart failure is both common and associated with worse symptoms and increased mortality. Several small randomized controlled trials (RCTs) have assessed erythropoiesis-stimulating agents (ESAs), but definitive evaluation and clinical guidance are required. We sought to systematically review the effects of ESAs in chronic heart failure. METHODS: An extensive search strategy identified 11 RCTs with 794 participants comparing any ESA with control over 2 to 12 months of follow-up...
May 2011: American Heart Journal
https://read.qxmd.com/read/16298261/anemia-and-heart-failure-in-chronic-kidney-disease
#34
REVIEW
Francesco Locatelli, Pietro Pozzoni, Lucia Del Vecchio
Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic kidney disease (CKD) patients on dialytic treatment. Anemia is an early complication of CKD and, by inducing important cardiovascular alterations, first of all left ventricular hypertrophy, it does not only impair quality of life, but has also been shown to be an independent risk factor for adverse cardiovascular outcomes in CKD patients. Clinical studies, although with discordant results, have shown that cardiovascular benefits, mainly in terms of left ventricular hypertrophy regression, may be achieved by a partial correction of hemoglobin levels, however, it still is unclear whether starting anemia correction in a very early phase of CKD or aiming for complete normalization of hemoglobin levels higher than the targets recommended by current guidelines may provide further cardiovascular advantages...
November 2005: Seminars in Nephrology
https://read.qxmd.com/read/24959595/heart-failure-in-patients-with-chronic-kidney-disease-a-systematic-integrative-review
#35
REVIEW
Liviu Segall, Ionut Nistor, Adrian Covic
INTRODUCTION: Heart failure (HF) is highly prevalent in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and is strongly associated with mortality in these patients. However, the treatment of HF in this population is largely unclear. STUDY DESIGN: We conducted a systematic integrative review of the literature to assess the current evidence of HF treatment in CKD patients, searching electronic databases in April 2014. Synthesis used narrative methods...
2014: BioMed Research International
https://read.qxmd.com/read/12480972/the-effect-of-correction-of-anaemia-in-diabetics-and-non-diabetics-with-severe-resistant-congestive-heart-failure-and-chronic-renal-failure-by-subcutaneous-erythropoietin-and-intravenous-iron
#36
COMPARATIVE STUDY
Donald S Silverberg, Dov Wexler, Miriam Blum, Joseph Z Tchebiner, David Sheps, Gad Keren, Doron Schwartz, Ron Baruch, Tatyana Yachnin, Meital Shaked, Idit Schwartz, Shoshanna Steinbruch, Adrian Iaina
BACKGROUND: A mild anaemia is often found in patients with congestive heart failure (CHF), but its significance is uncertain. In an open uncontrolled study we investigated the effect of correcting this anaemia [haemoglobin (Hb) 9.5-11.5 g%] with subcutaneous (s.c.) erythropoietin (Epo) and intravenous (i.v.) iron (Fe) in 179 patients, 84 type II diabetics and 95 non-diabetics, with moderate to severe CHF which was resistant to maximally tolerated doses of standard CHF medications. METHODS: Epo, s...
January 2003: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/23487165/darbapoetin-alfa-does-not-help-adults-with-heart-failure-and-anaemia
#37
(no author information available yet)
No abstract text is available yet for this article.
2013: BMJ: British Medical Journal
https://read.qxmd.com/read/24656105/anemia-and-iron-deficiency-in-heart-failure
#38
REVIEW
Natasha P Arora, Jalal K Ghali
Anemia is a common comorbidity in patients with heart failure (HF) and is associated with poor prognosis. Iron deficiency, with or without anemia, confers increased risk of mortality and morbidity. Along with the altered iron metabolism in HF patients, inflammation creates challenges in the interpretation of laboratory parameters used to diagnose anemia in HF. Since the RED-HF trial failed to demonstrate any benefit from the use of erythropoiesis-stimulating agents (ESAs) on mortality or morbidity in HF patients, ESAs are no longer considered a treatment option, although intravenous iron has potential as therapy for anemic and nonanemic HF patients...
April 2014: Heart Failure Clinics
https://read.qxmd.com/read/17437743/anemia-as-a-risk-factor-for-kidney-function-decline-in-individuals-with-heart-failure
#39
RANDOMIZED CONTROLLED TRIAL
Nisha Bansal, Hocine Tighiouart, Daniel Weiner, John Griffith, Panagiotis Vlagopoulos, Deeb Salem, Adeera Levin, Mark J Sarnak
Chronic kidney disease (CKD), anemia, and declining kidney function are recognized as risk factors for adverse outcomes in patients with heart failure. This analysis was conducted to evaluate whether anemia is a risk factor for kidney function decrease in patients with heart failure. Data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized trial of enalapril versus placebo in patients with ejection fractions <or=35%, were analyzed. After randomization, creatinine measurements were taken at 2 weeks, 6 weeks, 4 months, and every 4 months thereafter...
April 15, 2007: American Journal of Cardiology
https://read.qxmd.com/read/18703380/the-role-of-correction-of-anaemia-in-patients-with-congestive-heart-failure-a-short-review
#40
REVIEW
Donald S Silverberg, Dov Wexler, Adrian Iaina, Doron Schwartz
Many patients with Congestive Heart Failure (CHF) are anaemic. This anaemia is associated with more severe CHF and a higher incidence of mortality, hospitalisation and morbidity. The only way to prove that the anaemia is causing this worsening of CHF is to correct it. We review here some of the published papers about correction of anaemia. Many studies show a positive effect of Erythropoietin (EPO) or its' derivatives when administered in combination with oral or IV iron, with improvements in left and right ventricular systolic and diastolic function, dilation and hypertrophy and renal function...
September 2008: European Journal of Heart Failure
label_collection
label_collection
2811
2
3
2014-08-26 02:03:26
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.